Mark Schulte, MD
Rheumatology · West Seneca, NYNPI 1093973471
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $946, 2.6 times the $365 reported in 2019.
Across 225 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$694
- Pfizer$448
- AbbVie$418
- Amgen$413
- UCB, Inc.$202
- AstraZeneca$193
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 87 | $694 |
| Pfizer | 37 | $448 |
| AbbVie | 16 | $418 |
| Amgen(2 entities) | 20 | $413 |
| UCB, Inc. | 7 | $202 |
| AstraZeneca(2 entities) | 9 | $193 |
| GSK | 6 | $155 |
| Novartis | 6 | $131 |
| Radius Health, Inc. | 4 | $111 |
| Boehringer Ingelheim | 4 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Genentech USA, Inc. | 4 | $77 |
| Sandoz | 2 | $69 |
| Lilly USA, LLC | 3 | $59 |
| Fresenius Kabi USA, LLC | 2 | $54 |
| Aurinia Pharma U.S., Inc. | 2 | $47 |
| Octapharma USA, Inc. | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Sanofi | 1 | $34 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Invivyd Inc | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Sobi, Inc | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
How this compares
$3,530 in reported general payments places this provider in the 55th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 48 | $348,162 |
| RinvoqUpadacitinib | 30 | $299,782 |
| Humira(Cf) PenAdalimumab | 20 | $205,206 |
| Xeljanz XrTofacitinib Citrate | 26 | $139,589 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $122,826 |
| EnbrelEtanercept | 14 | $101,148 |
| BenlystaBelimumab | 18 | $83,498 |
| Orencia ClickjectAbatacept | 13 | $71,931 |
| OtezlaApremilast | 12 | $60,008 |
| KevzaraSarilumab | 11 | $42,715 |
| ProliaDenosumab | 11 | $17,523 |
| MethotrexateMethotrexate Sodium | 500 | $13,606 |
| Hydroxychloroquine Sulfate | 178 | $8,284 |
| Febuxostat | 20 | $6,117 |
| Celecoxib | 160 | $5,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $418 | $299,78230 claims |
| AmgenEnbrel, Otezla, Prolia | $413 | $178,67937 claims |
| GSKBenlysta | $155 | $83,49818 claims |
| SanofiKevzara | $34 | $42,71511 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $20 | $1,09533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 541 rheumatology providers in New York.
Other rheumatology in West Seneca
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
- Sanjay GodhwaniWading River$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.